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To the Editor: In their recent paper, Hemkens et al.
conclude that their ‘results based on observational data
support safety concerns surrounding the mitogenic proper-
ties of glargine in diabetic patients’, because given ‘the
overall relationship between insulin dose and cancer, and
the lower dose with glargine, the cancer incidence with
glargine was higher than expected compared with human
insulin’ [1]. Indeed, if it is obvious that the mean daily
insulin dose was lower in insulin glargine compared with
human insulin users (25.9±22.5 vs 43.8±37.4 IU), and if,
using models to adjust for a few potential confounders, a
higher incidence of malignant neoplasms was found with
insulin glargine at similar insulin dose, in our opinion, this
does not support any safety concern surrounding the
mitogenic properties of insulin glargine in diabetic patients.
I will demonstrate this in two steps.
First, over-adjustment for insulin doses should be
considered. Unfortunately, Hemkens et al. did not report
data concerning glycaemic control. If identical glycaemic
control had been obtained in the treatment groups, using
lower doses in insulin glargine users, adjustment for insulin
dose would not have been appropriate. However, two
randomised clinical trials in which insulin glargine and
NPH insulin were up-titrated to reach identical glycaemic
targets have shown no difference between insulin glargine
and human insulin in terms of the dose needed: 68±39 vs
70±42 IU (NS) in the Lantus plus Metformin (LANMET)
Study [2], and 32.1±17.6 vs 32.8±18.9 IU (NS) in the
Lantus Evaluation in Asian Diabetics (LEAD) Study [3],
respectively. Furthermore, the Treat-to-Target Trial reported
that higher doses of insulin glargine were needed:
47.2±24.9 vs 41.8±25.6 IU (p<0.005) [4]. Therefore, the
hypothesis of over-adjustment can be ruled out, and it can
be deduced that poorer glycaemic control was achieved in
the insulin glargine-treated group in the study by Hemkens
and colleagues [1], as it was in the Scottish diabetic
population studied [5]. It is thus important to understand the
reason why a higher glycaemic target was set for the
patients treated with insulin glargine. As a positive
association between the length of exposure to high levels
of plasma glucose and the risk of developing diabetes-
related microvascular complications has been demonstrated
[6] and is well known by physicians, the most probable
explanation for the less ambitious glycaemic control aimed
for in the insulin glargine-treated group is that these
patients were considered by their practitioners to have a
shorter life expectancy than those treated by other insulin
regimens. This suggests an allocation bias to be present in
the study by Hemkens et al. [1], as acknowledged by the
SDRN Epidemiology Group in the Scottish paper [5]. As
the insulin glargine users were not older than the human
insulin users (69.5±11.6 vs 69.6±13.1 years, respectively),
it probably means that they were in worse health. This is
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Table 1 of the paper by Hemkens et al., which were used
for multiple adjustments. Therefore, one can only speculate
on the reasons why the insulin glargine-treated patients
were supposed to have a shorter life-expectancy in their
practitioner’s mind, and can only imagine the character-
istics that differed between the two groups at baseline that
could not, unfortunately, be adjusted for. As the authors
conclude that there is a higher cancer incidence during the
very short follow-up period (mean 1.63 years, median
1.41 years), a possible explanation, the simplest, is that, at
least for some of the diabetic patients treated with insulin
glargine, the practitioner knew they had a cancer that was
not yet registered in the health insurance fund. Indeed, this
provocative suggestion becomes plausible when one exam-
ines the procedures used to select ‘adult patients without
known malignant disease’, as the authors state that they
‘considered participants to be without known malignant
disease if they had not received a corresponding diagnosis
within 3 years prior to inclusion in the study’, and that they
‘excluded participants with the slightest suspicion of a
malignant disease (e.g. patients with the ICD-10 [Interna-
tional Classification of Diseases, 10th revision, German
Modification] diagnosis Z03.1—observation for suspected
malignant neoplasm)’ [1]. This information seems to mean
that the coding forms in the hospital records were the only
source for diagnosing a previous cancer and to exclude an
insulin-treated diabetic patient. Table 1 of the paper [1]
shows that the insulin glargine-treated patients had been
hospitalised less often than the human insulin users in the
three preceding years (35.5% had one or two hospital stays,
and 16.2% had more than two hospital stays vs 41.3% and
23.4%, respectively, p<0.0001). Thus, the explanation for
the results reported could be that some diabetic patients
having a recent cancer were included by error. Their
practitioner knew they had cancer, treated them with insulin
glargine and set the glycaemic target at a higher level, using
lower insulin doses. As they had not yet been hospitalised,
cancer had not been notified to the health insurance fund.
Second, in spite of multiple comparisons and multiple
models, we are told that because the study was intended to
generate hypotheses, no adjustments were made for
multiple testing’ [1], and a paper whose author list includes
Bender, a coauthor of the Hemkens et al. study, is cited to
justify that decision [7]. In the paper by Bender and Lange
it is written that ‘“Significant” results based upon explor-
atory analyses should clearly be labelled as exploratory
results. To confirm these results the corresponding
hypotheses have to be tested in further confirmatory
studies.’ [7]. Indeed, even if we can accept this opinion in
general, which could be challenged, it is unacceptable in
the situation of diabetes treatment and cancer risk, as no
confirmatory study using a randomised design can be
performed now or in the future to validate, or, more
probably, to refute the hypothesis of a causal association
between insulin glargine and cancer risk, for obvious
ethical and practical reasons. Therefore, to have raised a
scientific issue that will never be resolved, by using a
flawed methodology, is unethical.
In conclusion, probably the right and safe decision
would have been to adopt the opinion of the three of the
six referees who initially recommended rejection [8], and
not publish the study by Hemkens et al., especially given
that the Editorial accompanying the publication states:
‘There is no evidence of an overall increase in the rate of
cancer development in patients on insulin glargine, and
some suggestion that the risk may actually be reduced.’ [8].
Unfortunately, the rumour is spreading now, and it is a pity
to have troubled for a long time, probably forever, many
diabetic patients who were using glargine insulin, often
with great satisfaction, as well as their care providers.
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